Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

NCT03126435 is registered in ClinicalTrials.gov with SynCore Biotechnology Co., Ltd. as lead sponsor.

NCT NCT03126435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03126435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Lead sponsor
SynCore Biotechnology Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 16, 2018
Completion date
October 8, 2021
Enrollment
218 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic cancer, metastatic pancreas cancer, pancreatic adenocarcinoma